Heart Valve Diseases: Clinical Trials

101 trials for Heart Valve Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

45 completed, 16 unknown, 14 terminated, 8 active not recruiting. 101 Phase 3, 21 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3101Completed 45, Unknown 16, Terminated 14, Active not recruiting 8, Recruiting 8, Not yet recruiting 5, Withdrawn 3, Enrolling by invitation 1, Suspended 1
Phase 221Completed 7, Terminated 5, Unknown 4, Recruiting 2, Enrolling by invitation 1, Suspended 1, Withdrawn 1

Follow Heart Valve Diseases: new trials by email Literature Review of Heart Valve Diseases trials Research Report on Heart Valve Diseases

Trials (filtered) newest first · largest first

All 101 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety and Efficacy of Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (SOLSTICE-HCM)
Mavacamten, Placebo - Non-obstructive Hypertrophic Cardiomyopathy
Phase 3Not yet recruitingBristol-Myers Squibb5002026-12-292026-11-17
BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy
BHB-1893, Metoprolol - Cardiomyopathy, Hypertrophic Obstructive
Phase 3RecruitingBraveheart Bio, Inc.2102026-09-022026-11-10
Effects of VALsartan On atRIAl Mitral Regurgitation (VALORIA) - Pilot
Valsartan, Placebo - Atrial Functional Mitral Regurgitation
Phase 2 / Phase 3RecruitingJonathan Beaudoin502026-07-132026-08-20
Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement
Wegovy ®, Placebo - Aortic Stenosis, Heart Failure
Phase 3Not yet recruitingLeiden University Medical Center8262026-04-012025-07-29
Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR
Apixaban, Warfarin - Valve Disease, Heart, Atrial Fibrillation (AF)
Phase 3Not yet recruitingMeshalkin Research Institute of Pathology of Circulation1202026-02-012026-02-25
LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
Anticoagulant treatment Rivaroxaban, Best medical therapy - Hypertrophic Cardiomyopathy (HCM)
Phase 3RecruitingRennes University Hospital5322026-01-072026-06-12
DIrect Oral Anticoagulation and Bioprothesis Aortic Valve
Apixaban 5 MG Oral Tablet, Aspirin 75 to 100mg once a day - Aortic Valve Disease
Phase 3Not yet recruitingAssistance Publique - Hôpitaux de Paris15002025-09-012025-06-12
A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
HRS-1893 Tablets, HRS-1893 Placebo Tablets - Obstructive Hypertrophic Cardiomyopathy
Phase 3Active not recruitingShandong Suncadia Medicine Co., Ltd.2282025-08-112026-08-24
A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
BAY3723113 - Obstructive Hypertrophic Cardiomyopathy
Phase 3Active not recruitingBayer362025-06-302026-10-23
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
Ataciguat, Placebo - Moderate Aortic Valve Stenosis
Phase 2 / Phase 3RecruitingKardigan, Inc.12762025-06-272026-07-06
Antagonization of Heparin With Protamine Sulfate After TAVI
Antagonization of heparin with protamine sulfate - Aortic Valve Stenosis, Heart Valve Diseases
Phase 3RecruitingAssistance Publique - Hôpitaux de Paris9402025-05-252025-08-22
Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring
ATP-C135, ATP-C75 - Hypertrophic Cardiomyopathy
Phase 3Not yet recruitingYonsei University1002025-03-012025-03-13
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
Inclisiran, Placebo - Familial Hypercholesterolemia - Homozygous
Phase 3RecruitingNovartis Pharmaceuticals92025-02-282026-07-24
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
Inclisiran, Placebo - Familial Hypercholesterolemia - Heterozygous
Phase 3RecruitingNovartis Pharmaceuticals602024-12-092026-05-15
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
Sotagliflozin, Placebo - Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
Phase 3Active not recruitingLexicon Pharmaceuticals5002024-09-242026-08-26
The Role of SGLT2i in Management of Moderate AS
Empagliflozin 10 MG - Moderate Aortic Valve Stenosis
Phase 2 / Phase 3CompletedUniversity of East Anglia1042024-05-302026-07-28
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Mavacamten, Placebo - Cardiomyopathy, Hypertrophic
Phase 3Active not recruitingBristol-Myers Squibb442024-04-172025-12-19
Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis
PCSK9 inhibitors and statins with or without ezetimibe, Statins with or without ezetimibe - Aortic Stenosis
Phase 3RecruitingBeijing Anzhen Hospital1602024-03-222024-05-09
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
Aficamten - Obstructive Hypertrophic Cardiomyopathy
Phase 3CompletedCorxel Pharmaceuticals402023-11-142026-01-21
Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
Enavogliflozin, Placebo - Tricuspid Regurgitation, Heart Failure With Preserved Ejection Fraction
Phase 3Active not recruitingAsan Medical Center5412023-10-252025-12-29

Showing 20 of 101. Sign in to see all of them.

Narrower conditions

Aortic Valve Stenosis (37)  ·  Cardiomyopathy, Hypertrophic (27)  ·  Heart Failure (10)  ·  Mitral Valve Insufficiency (9)  ·  Atrial Fibrillation (6)  ·  Cardiovascular Diseases (6)  ·  Coronary Artery Disease (6)  ·  Hypertrophy, Left Ventricular (6)  ·  Tricuspid Valve Insufficiency (5)  ·  Aortic Valve Disease (4)  ·  Mitral Valve Stenosis (4)  ·  Aortic Valve Insufficiency (3)  ·  Bicuspid Aortic Valve Disease (3)  ·  Heart Diseases (3)

Broader conditions

Heart Diseases (98)  ·  Cardiovascular Diseases (95)  ·  Aortic Valve Disease (67)  ·  Ventricular Outflow Obstruction (35)  ·  Aortic Stenosis, Subvalvular (27)  ·  Aortic Valve Stenosis (27)  ·  Cardiomyopathies (27)  ·  Pathological Conditions, Signs and Symptoms (21)  ·  Vascular Diseases (16)  ·  Pathologic Processes (15)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8)  ·  Arterial Occlusive Diseases (7)  ·  Arteriosclerosis (7)  ·  Cardiomegaly (7)

Interventions

MYK-461 (8)  ·  apixaban (5)  ·  Aspirin (4)  ·  Atorvastatin (4)  ·  Metoprolol (4)  ·  Rivaroxaban (4)  ·  Warfarin (4)  ·  Clopidogrel (3)  ·  Saline Solution (3)  ·  empagliflozin (3)  ·  ALN-PCS (2)  ·  Atenolol (2)  ·  Colchicine (2)  ·  Dexmedetomidine (2)  ·  Perhexiline (2)

Sponsors

Assistance Publique - Hôpitaux de Paris (6)  ·  Bristol-Myers Squibb (6)  ·  Asan Medical Center (3)  ·  Cytokinetics (3)  ·  Charite University, Berlin, Germany (2)  ·  National Institute of Cardiology, Warsaw, Poland (2)  ·  Novartis Pharmaceuticals (2)  ·  Oslo University Hospital (2)  ·  Ottawa Heart Institute Research Corporation (2)  ·  Rajaie Cardiovascular Medical and Research Center (2)  ·  Sorin Group USA, Inc. (2)  ·  University Hospital Birmingham (2)  ·  University Hospital, Bordeaux (2)  ·  Artivion Inc. (1)  ·  Astana Medical University (1)

Countries

United States (25)  ·  France (24)  ·  Canada (21)  ·  Germany (18)  ·  United Kingdom (17)  ·  Netherlands (14)  ·  China (13)  ·  Italy (13)  ·  Spain (12)  ·  Israel (11)  ·  Denmark (10)  ·  Poland (10)  ·  Czechia (9)  ·  Portugal (8)  ·  Brazil (7)

Top investigators

Jian-an Wang, MD,PhD (2)  ·  Ade Meidian Ambari, MD,FIHA (1)  ·  Alex Zapolanski, MD (1)  ·  Ali Khoynezhad, MD (1)  ·  Alibek Kh Mustafin, Professor (1)  ·  An Aldia Asrial, MD (1)  ·  Andre Duraes, PhD (1)  ·  Andrew Maitland, MD (1)  ·  Arturo Evangelista-Masip, MD, PhD, Professor (1)  ·  Aun-Yeong Chong, MD, MRCP (1)  ·  Brian P O'Neill, MD (1)  ·  Carolyn Y Ho, MD (1)

Results publications

PMID 42636950, PMID 39217450, PMID 42624353, PMID 16500110, PMID 16539843, PMID 18341239, PMID 18765432, PMID 19580719, PMID 20413039, PMID 20628774, PMID 20659762, PMID 21353251, PMID 22147903, PMID 22155702, PMID 22440214, PMID 22818065, PMID 22869821, PMID 23316326, PMID 23357717, PMID 23713888, PMID 24004961, PMID 24173271, PMID 24780909, PMID 24824357, PMID 24903982, PMID 25048345, PMID 25217488, PMID 25240525, PMID 25301859, PMID 25438232, PMID 25469804, PMID 25540059, PMID 25685360, PMID 26361154, PMID 26477635, PMID 26489804, PMID 26602073, PMID 27085434, PMID 27196464, PMID 27208464, PMID 27486164, PMID 27491438, PMID 27590665, PMID 28319871, PMID 28400935, PMID 28455295, PMID 28698175, PMID 28797414, PMID 29180457, PMID 29361285

NIH funding

2023 (4), 2015 (2), 2017 (1), K23HL078901 (1), U01HL084904 (1)